ArticleNPJ breast cancer2022

Patient-reported outcomes from a randomized trial of neoadjuvant atezolizumab-chemotherapy in early triple-negative breast cancer.

Carlos H Barrios et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.